2011 Gigi Shaw Arledge Conference on Pancreatic Disease

Infinity Pharmaceuticals is pleased to partially sponsor the Gigi Shaw Arledge Conference on Pancreatic Disease. Infinity is an innovative drug discovery and development company seeking to discover, develop, and deliver to patients best-in-class medicines for difficult-to-treat diseases. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. Infinity's innovative pipeline includes its oral Hedgehog pathway inhibitor, IPI-926, which is being developed for a broad range of cancers, including pancreatic cancer. Infinity expects to complete enrollment in its Phase 2 trial evaluating IPI-926 in combination with gemcitabine in previously untreated patients with metastatic pancreatic cancer by the end of 2011. For more information on Infinity, please visit www.infi.com.

MLV is a boutique investment bank and institutional broker-dealer focused on raising capital more efficiently for issuers in capital intensive industries. MLV has rapidly become a leader in At-the-Market (ATM) Offerings and the issuance of perpetual (non-convertible) preferred equity. MLV also aims to provide high quality sell-side research and independent investment advice.

Peregrine Pharmaceuticals, Inc. is proud to sponsor the cocktail reception at the Gigi Shaw Arledge Conference on Pancreatic Disease. Peregrine Pharmaceuticals is a clinical-stage biopharmaceutical company developing and manufacturing first-in-class monoclonal antibodies for the treatment of cancer and viral infections. Our lead candidate bavituximab targets phosphatidylserine (PS), an immunosuppressive molecule usually located inside cells which becomes exposed on the cells lining tumor blood vessels and virus-infected cells. Bavituximab is currently in four randomized Phase II clinical trials in non-small cell lung cancer, pancreatic cancer, and HCV, as well as four investigator-sponsored trials in additional oncology indications. In prior clinical studies, bavituximab in combination with chemotherapy has demonstrated promising tumor response and survival data. Our second clinical candidate Cotara has shown encouraging 8.8 month median overall survival in a Phase II trial in 41 recurrent glioblastoma multiforme patients. A novel, single-treatment approach to brain cancer, Cotara links a radioactive isotope to a monoclonal antibody that binds to the DNA/histone complex exposed by dead and dying cells found at the center of solid tumors, irradiating the tumor from the inside out, with minimal radiation exposure to healthy tissue. Peregrine has cGMP biomanufacturing capabilities through Avid Bioservices, a fully-integrated subsidiary that provides products for our clinical trials as well as clinical and commercial products for third-party clients.

RedPath Integrated Pathology is a genomics-based cancer diagnostics company that can resolve challenging cases for patients who may or may not have cancer. Our primary focus is clarifying the status of patients with pancreatic cystic lesions and masses. RedPath's PathFinderTG® analysis integrates a patented, multi-tiered DNA analysis with clinical data to provide unique diagnostic information. This approach enables gastroenterologists and gastrointestinal clinicians to obtain detailed diagnostic information to make more informed management decisions, thus improving patient care and reducing health care costs. PathFinderTG's greatest value for pancreatic lesions is when traditional diagnostic tests produce inconclusive results, such as indeterminate or inconsistent imaging, cytology or fluid chemistry.

Threshold Pharmaceuticals is proud to sponsor the faculty dinner for the Gigi Shaw Arledge Conference on Pancreatic Disease. Since its founding in 2002, Threshold has been focused on developing therapeutics that target the unique metabolic properties of solid tumors as well as some hematologic malignancies. Our novel hypoxia-targeted prodrug, TH-302, is currently being evaluated in a controlled Phase 2 clinical trial in combination with gemcitabine in patients with pancreatic cancer, with top-line results expected by the end of this year. In addition, the company has ongoing clinical studies with TH-302 in a variety of other cancers, both as monotherapy as well as in combination with several other approved agents. Additional information about Threshold Pharmaceuticals and its clinical programs can be found at www.thresholdpharm.com.

Transnetyx provides Researchers with essential genetic testing involving mutant mouse lines. Our automated genotyping service continues to build a reputation for accuracy and efficiency in the world of bio-scientific research utilizing qPCR.

Transnetyx clears the way for Investigators to concentrate on what is most important to them – their research. With more than 22 million successful reactions, Transnetyx eliminates the tedious process of extracting and testing DNA. Utilizing our automated process not only replaces the need for supplies and reagents, but also eliminates the possibility for human error or contamination. For more information, please visit www.Transnetyx.com.

VisualSonics is the undisputed world leader in real-time, in vivo, micro-imaging systems, providing modalities specifically designed for preclinical cancer research. Our systems deliver outstanding image quality and resolution down to the cellular level. These tools provide fast, accurate 3D tumor sizing, biomarker analysis, and sophisticated angiogenesis / tumor perfusion quantification.

The Lustgarten Foundation, based in Bethpage, New York, is America's largest private foundation dedicated solely to funding pancreatic cancer research.
Founded in 1998, the Foundation provides critical support in the search for better diagnostics and treatment of pancreatic cancer, and to date has provided more than $38 million to more than 125 research projects at 41 medical and research centers worldwide. Cablevision Systems Corporation, a leading media and entertainment company, underwrites all of The Lustgarten Foundation's administrative costs to ensure that 100 percent of every dollar donated goes directly to pancreatic cancer research. For more information, please visit www.lustgarten.org.

The Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic cancer.

We create hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. The organization raises money for direct private funding of research–and advocates for more aggressive federal research funding of medical breakthroughs in prevention, diagnosis and treatment of pancreatic cancer.

The Pancreatic Cancer Action Network fills the void of information and options by giving patients and caregivers reliable, personalized information they need to make informed decisions. The organization helps support individuals and communities all across the country work together to raise awareness and funds to find a cure for pancreatic cancer. We create a sense of hope and community so no one has to face pancreatic cancer alone. For more information, please visit www.pancan.org.

Founded in 1817, the New York Academy of Sciences is one of the oldest scientific institutions in the United States. The Academy is an independent 501(c)(3) nonprofit, scientific, and educational organization with a history of fostering new collaborations among key stakeholders and emerging experts in academia, industry, and government in order to drive advances in science, medicine, technology, innovation, and sustainability. Through our diverse portfolio of interdisciplinary scientific conferences and seminars, career development and public outreach programs, and global dissemination of the latest scientific breakthroughs via innovative print and electronic media, we engage an informed and diverse membership community that encompasses more than 25,000 individuals in 140 countries. Visit the Academy at www.nyas.org.